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CASE REPORT / OLGU SUNUMU
Successful management of a patient with toxic epidermal necrolysis by high dose 
intravenous immunoglobulin
Toksik epidermal nekrolizisli bir hastanın yüksek doz intravenöz immünglobulin ile başarılı 
tedavisi
Ali Güneş, İlyas Yolbaş, Selvi Kelekçi, Servet Yel, Cahit Şahin, Aydın Ece
ÖZET
Toksik  epidermal  nekrolizis  (TEN)  sıklıkla  ilaç  kullanı-
mı sonucu gelişen, akut başlangıçlı, çok hızlı ilerleyen, 
epidermis nekrozu ile karakterize bir hastalıktır. Şiddet-
li  seyreden  olgularda  mortalite  oranı  %20-60  arasında 
değişir.  Kesin  tedavisi  olmamasına  rağmen  intravenöz 
immünglobulin (İVİG) tedavisinin etkili olduğunu belirten 
yayınlar mevcuttur. Bu çalışmada; ibuprofen, metronida-
zol, klaritromisin ve prokain penisilin kullandıktan üç gün 
sonra deri döküntüleri başlayan ve %50 oranında ikinci 
derecede yanık düzeyinde lezyonlar ile TEN tablosu geli-
şen 9 yaşında erkek hasta sunulmuştur. Hastaya verilen 
yüksek doz İVİG tedavisi ile düzelme sağlandı. Bu olgu 
TEN tedavisinde etkinliği tartışmalı olan İVİG tedavisine 
olumlu yanıt alınabileceğine bir örnektir.
Anahtar kelimeler: Toksik epidermal nekrolizis, intrave-
nöz immünglobulinler, çocuk
ABSTRACT
Toxic epidermal necrolysis (TEN) is a disease that mostly 
caused by drug use and characterized by acute onset and 
rapidly progressive necrosis of the epidermis. In severe 
cases, mortality rate change between 20% and 60%. Al-
though there is no definite treatment, some authors have 
reported the effectiveness of intravenous immunoglobu-
lin (IVIG). Here, we presented a 9-year-old male patient 
with TEN. Skin rashes of patient began after three days of 
using ibuprofen, metronidazole, clarithromycin, and pro-
caine penicillin. Skin lesions resembling second-degree 
burns covered 50% of the patient’s body surface area. Af-
ter giving high-dose IVIG, the patient’s lesions improved. 
This case is an example of effect of high dose IVIG in the 
treatment of TEN. J Clin Exp Invest 2013; 4 (4): 503-505
Key words: Toxic epidermal necrolysis, intravenous im-
munoglobulins, child
INTRODUCTION
Toxic epidermal necrolysis (TEN) is an acute onset, 
and  rapidly  progressive  disease  of  the  skin,  and 
mucous membranes characterized by necrosis of 
the epidermis. It may occur due to many causes 
such as drugs and infections. Mortality rate ranged 
from 20% to 60% [1]. The most common etiologic 
agents  are  drugs  such  as  antibiotics,  anticonvul-
sants, nevirapine, abacavir, and non-steroidal anti-
inflammatories. Measles, chickenpox, herpes zos-
ter, herpes simplex, Escherichia coli, Mycoplasma 
pneumoniae, aspergillosis, vaccines and malignant 
diseases are other etiologic causes [2]. There is still 
no definitive treatment proven effective in cases of 
TEN. Some previous studies reported that cortico-
steroids may improve the prognosis of TEN. The in-
creasing risk of secondary bacterial infection by this 
treatment leaded to alternative drugs and methods. 
For  this  purpose,  plasmapheresis,  cyclosporine, 
thalidomide, pentoxifylline, cyclophosphamide, and 
granulocyte colony-stimulating factor were tested. 
Recent reports draws attention to successful results 
by  intravenous  immunoglobulin  (IVIG)  therapy.  In 
this study, we presented a severe TEN case that 
dramatically gave response to high-dose IVIG ther-
apy.
CASE REPORT
A Nine-years-old male patient with common purple-
brown skin rashes and peeling skin complaints ad-
mitted to our hospital after three day of using ibu-
profen, metronidazole, clarithromycin, and procaine 
penicillin for the treatment of upper respiratory tract 
infection and gastroenteritis. On physical examina-
tion, there were poor general condition, impairment 
of  consciousness,  39ºC  body  temperature,  140 
heartbeat per minute, hyperemic oropharynx, hem-Güneş et al. IVIG for toxic epidermal necrolysis 504
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orrhagic lesions in the mouth, bilateral edematous 
eyelids, hyperemic conjunctivae, and coarse crack-
les on lung oscultation. In addition, there were bul-
lous lesions, peelings locally subcutaneous hemor-
rhages on face, lips and all over the body (Figure 1).
Figure 1. An image of case at hospitalization
On the laboratory examination, there were hy-
poalbuminemia 2.5 g/dL (normal limits, NL: 3.5-5.0 
g/dL), hypocalcemia (7.1 mg/dL, NL: 8.4-10.2 mg/
dL),  hyperglycemia  (202  mg/dL,  NL:  70-109  mg/
dL), hyperamylasemia (650 U/L, NL: 25 to 125 U/L), 
high C-reactive protein (18.5 mg/dL, NL: 0 to 8 mg/
dL), normal level of total IgE: 312 IU/mL, high level 
of D-dimer (484 mg/L, NL: <279 mg/L), leucope-
nia (3,800/mm3; NL: 4.4 to 11.3/mm3). There were 
70% neutrophils and 30% lymphocyte on periph-
eral blood smear. Liver and kidney function tests, 
and electrolytes were within normal limits. Labora-
tory examinations on the fifth day of hospitalization 
showed; albumin 2.3 mg/dL, total amylase 451 U/L 
(NL: 25 to 125 U/L), pancreatic amylase 63 U/L (NL: 
8 to 53 U/L), LDH 418 U/L (NL: 200 to 450 U/L), 
PTZ: 16.5 sec (NL: 9.5 to 13 sec), INR 1.35 sec (NL: 
0.88 to 1.2 sec), APTT 21.5 sec (NL: 25 to 35 sec), 
and erythrocyte sedimentation rate 67 mm/h. Skin, 
blood, urine and wound cultures were negative. Gr-
uber Widal (for salmonellosis) and Wright (for bru-
cellosis) tests and cytomegalovirus, toxoplasmosis 
and  malaria  tests  were  negative.  There  were  no 
abnormal findings in the bone marrow examination 
except increasing myeloid series due to infection.
Patients  were  admitted  to  the  intensive  care 
unit. Primarily all old medications were stopped. Pa-
tient’s wounds were dressed daily. Dental care was 
performed  for  oral  lesions.  Intravenous  immuno-
globulin (2 g/kg/day) was administered to patient for 
a period of four days. Vancomycin (45 mg/kg/d) was 
added therapy for persistent fever. On the tenth day 
of hospitalization, patient’s lesions regressed a little 
bit.  The  twenty-fifth  day  of  hospitalization  patient 
was discharged when lesions and clinical findings 
recovered (Figure 2). At the first control examination 
following two weeks of discharge, there was no sign 
of disease except for some scleral adhesions and 
hypopigmented areas of previous skin lesions.
Figure 2. An image of case at discharge from hospital
DISCUSSION
Toxic  epidermal  necrolysis  is  an  emergency  life-
threatening  dermatologic  disease  that  character-
ized by necrosis of two or more mucosal surface’s 
epidermis of more than 30% of the skin. The in-
cidences  of  it  have  been  reported  between  0.5 
and 1.89/1.000.000. The drugs consisted 80-90% 
causes.
Previous  studies  have  reported  that  cortico-
steroids  improved  prognosis  of  TEN.  However, 
because  steroids  increase  the  risk  of  secondary 
bacterial infection, IVIG has been used as an alter-
native therapy. Recently, it has been reported that 
IVIG therapy gave successful results. Because high 
dose  IVIG  has  anti-inflammatory  activity,  IVIG  is 
preferred instead of corticosteroids in the children, 
in the elderly patients and immunocompromised pa-
tients [3].
There  is  a  consensus  that  keratinocyte  cell 
death in TEN is a result of apoptosis. It has been 
shown that IVIG has in vitro antibodies that blocking 
Fas and block apoptosis by preventing the forma-
tion of Fas-Fas ligand compound [4]. There is no 
consensus on standard protocols for use, dosage 
and regimens of IVIG in TEN due to lack of sufficient 
controlled  trials.  Effective  drug  doses  range  from 
0.2 to 2 g/kg/day [5]. In a study, it has been reported 
that administration of IVIG (0.6 to 0.7 g/kg/day) for 
four days, stopped the epidermal differentiation at 
4.8 days of initiation of therapy [6]. Başkan et al. Güneş et al. IVIG for toxic epidermal necrolysis 505
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[7] administered 0.6 to 0.7 g/kg/day IVIG, and plas-
mapheresis during 4-5 days to cases that could not 
treated by pulse steroids. No complications were re-
ported due to IVIG therapy. They reported that IVIG 
stopped the formation of bullous and epidermal de-
tachment [7]. In addition, Tukenmez et al. [8] report-
ed IVIG therapy with positive results in two cases 
with TEN. In a multicenter study, Prins et al. found 
that in the early period high-dose IVIG infusion was 
safe, well-tolerated and an effective treatment mo-
dality in cases with TEN [9]. Mittmann et al. [10] re-
viewed a total of 17 articles about the effectiveness 
of IVIG in cases with Steven Johnson syndrome or 
TEN, and reported that IVIG was helpful in these 
cases. Our case supported previous reports.
In conclusion, although there is no certain treat-
ment option for TEN, IVIG therapy may be an effec-
tive and safe alternative therapy for pediatric cases 
with TEN.
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